We therefore aimed to develop and validate a risk score-based model to predict absolute risk reductions in kidney disease progression when treated with SGLT2 inhibitors in a lower-risk population with no established CVD and no or early-stage CKD (preserved eGFR and normal uACR/low-level albuminuria). This evidence concerns the gene SLC5A2 and chronic kidney disease.